Research Article
HBV-DNA Load-Related Peritumoral Inflammation and ALBI Scores Predict HBV Associated Hepatocellular Carcinoma Prognosis after Curative Resection
Table 4
Clinical backgrounds of HBV-related hepatocellular carcinoma (n=538).
| | Characteristics | Treated cohort (n=98) | Untreated cohort (n=440) | P-value |
| | Age, yr, median, (range) | 52.2 (22.0-75.0) | 52.1 (19.0-75.0) | 0.747 | | Gender (Female/Male) | 12/86 (12.2%/87.8%) | 64/376 (14.5%/85.5%) | 0.633 | | Cirrhosis (yes/no) | 83/15(84.7%/15.3%) | 385/55 (87.5%/12.5%) | 0.506 | | ALTU/L, median (range) | 42.0 (9.0-561.0) | 39.0 (8.0-848.0) | 0.410 | | AST, U/L, median (range) | 37.0 (15.0-517.0) | 36.0 (10.0-527.0) | 0.957 | | GGT, U/L, median (range) | 55.0 (16.0-610.0) | 59.0 (7.0-624.0) | 0.970 | | ALB, g/L, median (range) | 43.0 (28.0-59.0) | 43.0 (34.0-52.0) | 0.276 | | TBIL, μmol/L, median (range) | 13.6 (6.2-45.3) | 13.2 (2.6-130.0) | 0.176 | | Child-Pugh grade (A/B) | 97/1 (99.0%/1.0%) | 439/1 (99.8%/0.2%) | 0.331 | | HBV-DNA load | 35/63 (35.7%/64.3%) | 147/293 (33.4%/66.6%) | 0.723 | | (≤104/>104 copies/ml) | | HBV-ALBI (I/II/III/IV) | 29/54/6/9 | 118/211/40/71 | 0.213 | | (29.6%/55.1%/6.1%/9.2%) | (26.8%/48.0%/9.1%/16.1%) | | HBV-PIS (I/II/III/IV) | 15/27/19/37 | 125/138/66/111 | 0.011 | | (15.3%/27.5%/19.4%/37.8%%) | (28.4%/31.4%/15.0%/25.2%) | | AFP, ng/ml, (≤20/>20) | 38/60(38.8%/61.2%) | 179/261 (40.7%/59.3%) | 0.820 | | Platelet, 109/L, median (range) | 141.0 (44.0-408.0) | 137.0 (10.0-333.0) | 0.157 | | HBsAg (Positive/Negative) | 84/14 (85.7%/14.3%) | 363/77 (82.5%/17.5%) | 0.551 | | Tumor number (single/multiple) | 90/8 (91.8%/8.2%) | 392/48 (89.1%/10.9%) | 0.583 | | Microvascular invasion (yes/no) | 22/76 (22.4%/77.6%) | 125/315 (28.4%/71.6%) | 0.260 | | Tumor capsule(complete/Inomplete) | 54/44 (55.1%/44.9%) | 240/200 (54.5%/45.5%) | 1.000 | | Tumor size, cm (≤3/>3) | 38/60 (38.8%/61.2%) | 199/241 (45.2%/54.8%) | 0.262 | | AJCC stage (I-II/IIIA) | 86/12 (87.8%/12.2%) | 328/112 (74.5%/25.5%) | 0.005 | | BCLC stage (0-A/B-C) | 73/25 (74.5%/25.5%) | 293/147 (66.6%/33.4%) | 0.151 |
|
|
ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transpeptidase; ALB: Albumin; TBIL: total bilirubin; HBV-ALBI: hepatitis B virus load related ALBI score; HBV-PIS: hepatitis B virus load related peritumoral inflammatory score; AFP: alpha fetoprotein; HBsAg: hepatitis B virus surface antigen; AJCC: American Joint Committee on Cancer; BCLC: Barcelona Clinic Liver Cancer.
|
